[go: up one dir, main page]

MX2013005801A - Assays and biomarkers for lrrk2. - Google Patents

Assays and biomarkers for lrrk2.

Info

Publication number
MX2013005801A
MX2013005801A MX2013005801A MX2013005801A MX2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A
Authority
MX
Mexico
Prior art keywords
lrrk2
biomarkers
assays
screening
parkinson
Prior art date
Application number
MX2013005801A
Other languages
Spanish (es)
Inventor
Daisy Bustos
Donald Kirkpatrick
Tracy Kleinheinz
John Moffat
Zejuan Sheng
Shuo Zhang
Haitao Zhu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2013005801A publication Critical patent/MX2013005801A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)

Abstract

Biomarkers for screening subjects for Parkinson's disease and providing companion diagnostic tools for therapies using LRRK2 modulators, and assays for screening compounds and compositions for modulation of LRRK2 activity.
MX2013005801A 2010-11-30 2011-11-29 Assays and biomarkers for lrrk2. MX2013005801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41820810P 2010-11-30 2010-11-30
PCT/US2011/062468 WO2012075046A1 (en) 2010-11-30 2011-11-29 Assays and biomarkers for lrrk2

Publications (1)

Publication Number Publication Date
MX2013005801A true MX2013005801A (en) 2013-07-17

Family

ID=45217723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005801A MX2013005801A (en) 2010-11-30 2011-11-29 Assays and biomarkers for lrrk2.

Country Status (9)

Country Link
EP (1) EP2646819A1 (en)
JP (1) JP2014504362A (en)
KR (1) KR20130121903A (en)
CN (1) CN103348243A (en)
BR (1) BR112013013457A2 (en)
CA (1) CA2818428A1 (en)
MX (1) MX2013005801A (en)
RU (1) RU2013129818A (en)
WO (1) WO2012075046A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150153A1 (en) 2012-06-29 2015-02-05 Pfizer 7H-PIRROLO [2,3-d] PYRIMIDINES 4- (AMINO-SUBSTITUTED) NOVELTY AS LRRK2 INHIBITORS
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
US9582909B2 (en) * 2012-11-15 2017-02-28 Shimadzu Corporation Chromatograph mass spectrometry data processing device
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
JP6487921B2 (en) 2013-12-17 2019-03-20 ファイザー・インク Novel 3,4-disubstituted-1H-pyrrolo [2,3-b] pyridines and 4,5-disubstituted-7H-pyrrolo [2,3-c] pyridazines as LRRK2 inhibitors
KR102161364B1 (en) 2015-09-14 2020-09-29 화이자 인코포레이티드 Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
CN105331721A (en) * 2015-11-27 2016-02-17 首都医科大学宣武医院 Method for detecting PD (PD) pathogenic gene mutation, primer and kit thereof
KR102553188B1 (en) 2016-06-16 2023-07-11 데날리 테라퓨틱스 인크. Pyrimidin-2-ylamino-1H-pyrazole as an LRRK2 inhibitor for use in the treatment of neurodegenerative disorders
SG11202004019SA (en) 2017-11-17 2020-05-28 Cellix Bio Private Ltd Compositions and methods for the treatment of eye disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008016524A (en) 2006-06-20 2009-03-09 Novartis Ag Biomarkers for the progression of alzheimer's disease.
WO2008091799A2 (en) * 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
GB0706709D0 (en) * 2007-04-05 2007-05-16 Medical Res Council Methods
US20100175140A1 (en) * 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
EP2440559B1 (en) * 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
US8367349B2 (en) * 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2

Also Published As

Publication number Publication date
KR20130121903A (en) 2013-11-06
WO2012075046A9 (en) 2012-09-13
RU2013129818A (en) 2015-01-10
CA2818428A1 (en) 2012-06-07
JP2014504362A (en) 2014-02-20
EP2646819A1 (en) 2013-10-09
CN103348243A (en) 2013-10-09
BR112013013457A2 (en) 2017-07-11
WO2012075046A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
MX2013005801A (en) Assays and biomarkers for lrrk2.
WO2014042433A3 (en) Compounds and compositions for modulating adenosine a3 receptor activity
NZ612380A (en) Modulators of toll-like receptors
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2010135717A3 (en) Complement assays and uses thereof
MY161170A (en) Pyrimidine cyclohexyl glucocorticoid receptor modulators
MA34091B1 (en) Antibody antibody cd40
AU2016204248A1 (en) Boron-Containing Molecules
WO2014028461A3 (en) Treatment and diagnosis of melanoma
PH12014501108A1 (en) Anti-il-36r antibodies
NZ735173A (en) Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
MX2009008430A (en) Anti-robo4 antibodies and uses therefor.
WO2011095623A3 (en) miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
WO2014099979A3 (en) Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci
MX347853B (en) A rapid quantitative assay to measure cftr function in a primary intestinal culture model.
MX2015005448A (en) Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2).
MX2019000046A (en) Anti-il-23 antibodies.
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
JO3715B1 (en) Alpha 7 nicotinic acetylcholine receptor activator
WO2014052685A3 (en) Devices and methods for single cell analysis
WO2013082249A3 (en) Compositions and methods for prostate cancer analysis
WO2011106785A3 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
MX2010001187A (en) Modulators of ccr9 receptor and methods of use thereof.
AU2009235634A8 (en) Substituted sulfonamide derivatives
WO2013192522A3 (en) Biomarkers for tangle-predominant dementia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal